SMCI, MSTR, or UBER: Which Is the Most Attractive Large-Cap Stock?
Investors often look for opportunities to invest in large-cap stocks as they are generally associated with companies having a well-established business model and solid growth potential. The large-cap stocks have a market capitalization between $10 billion and $200 billion. Using TipRanks' Stock Comparison Tool, we placed Super Micro Computer (SMCI), Strategy (MSTR), and Uber Technologies (UBER) against each other to find the most attractive large-cap stock, according to Wall Street analysts.
Confident Investing Starts Here:
Super Micro Computer (NASDAQ:SMCI)
Super Micro Computer, or Supermicro, offers AI server and storage solutions. SMCI stock has rallied about 41% so far in 2025, with issues like delayed filing of financial statements and the threat of delisting in the rearview mirror.
In fact, investors are looking beyond the company's dismal results for the third quarter of Fiscal 2025, as they believe that SMCI is well-positioned to capture growth opportunities in the AI server market. Specifically, Super Micro Computer's DLC (direct liquid cooling) technology has an edge over rivals' offerings in terms of power and cost savings. Also, deals such as the $20 billion partnership with DataVolt to develop hyperscale AI campuses in Saudi Arabia and the U.S. have bolstered investors' confidence in SMCI stock.
What Is the Forecast for SMCI Stock?
Last month, Mizuho analyst Vijay Rakesh raised the price target for SMCI stock to $40 from $32 but retained a Hold rating. The 5-star analyst upgraded price targets for many AI server-related stocks to reflect increased demand and momentum across the supply chain.
While Rakesh acknowledges Super Micro Computer's leadership in AI server deployments, he maintains a neutral stance owing to intense rivalry and weak AI server margins.
Overall, Wall Street has a Moderate Buy consensus rating on Super Micro Computer stock based on six Buys, five Holds, and one Sell recommendation. The average SMCI stock price target of $40.83 indicates about 5% downside risk.
Strategy (NASDAQ:MSTR)
Strategy, earlier known as MicroStrategy, is the world's largest Bitcoin (BTC-USD) treasury company. It also offers AI-powered enterprise analytics software. MSTR stock is considered to be an attractive crypto play and an alternative to making a direct investment in the largest cryptocurrency, Bitcoin.
Interestingly, Strategy accumulates Bitcoin by using proceeds from equity and debt financings, as well as cash flows from its operations. Based on its latest purchase of 1045 Bitcoin units between June 3 and 8, Strategy now holds 582,000 BTC, having a value of $63.8 billion.
Is MSTR a Buy, Hold, or Sell?
Recently, TD Cowen analyst Lance Vitanza reiterated a Buy rating on Strategy stock with a price target of $590. Commenting on MSTR's offering for its Strife (STRF) preferred stock, the 5-star analyst stated that he expects this offering to create significantly greater accretion for common shareholders compared to the company's common stock and STRK (Strike) at-the-money offerings. Vitanza continues to view MSTR stock as a 'compelling vehicle for bitcoin investors.'
However, Monness analyst Gustavo Gala has a Sell rating on MSTR stock due to several reasons, including rising competition from companies like GameStop (GME), which are also following a Bitcoin-focused strategy.
Overall, Wall Street has a Strong Buy consensus rating on Strategy stock based on 12 Buys and one Sell recommendation. The average MSTR stock price target of $524.92 implies about 34.2% upside potential. MSTR stock has risen 35% year-to-date.
Uber Technologies (NYSE:UBER)
Ride-hailing and delivery platform Uber Technologies is impressing investors with its resilient performance despite macro challenges and intense competition. The company continues to strengthen its consumer base and enhance its profitability through strong top-line growth and operational efficiency.
Moreover, Uber addressed investors' fears about the impact of autonomous vehicle (AV) adoption on its ride-sharing business by turning it into an opportunity via multiple strategic deals, including that with Alphabet's (GOOGL) Waymo. On Tuesday, Uber announced a partnership with U.K.-based AV startup Wayve to launch a fully driverless robotaxi service in London.
Is UBER Stock a Buy or Sell Right Now?
Following the announcement of the launch date of Tesla's Robotaxi offering in Austin, BMO Capital analyst Brian Pitz reiterated a Buy rating on Uber Technologies stock with a price target of $101, calling it a Top Pick. The 5-star analyst stated that the pullback in UBER stock in reaction to this news was expected. That said, Pitz remains bullish on UBER stock due to its continued international expansion (including the purchase of Denmark's largest Taxi company, Dantaxi), persistent favorable trends for AV adoption in Austin, and ongoing innovation in both Mobility and Eats.
Pitz contends that investors' concerns look overblown, as recent data in Austin remains robust for Uber and the overall U.S. user base remains stable. Additionally, he highlighted that the difference in scale, with Tesla's (TSLA) initial strategy of 10-20 vehicles in Austin on Day 1 vs. hundreds of Waymo vehicles on the Uber platform in the upcoming months creating a favorable backdrop for Uber. Overall, Pitz believes that Uber Technologies remains an 'AV Winner,' with over 15 AV partners and the upcoming launch of shared AV Rides in 2026.
With 30 Buys and four Holds, Uber Technologies stock scores a Strong Buy consensus rating. The average UBER stock price target of $99 indicates a 15% upside potential. UBER stock has rallied 43% year-to-date.
Conclusion
Wall Street is highly bullish on Strategy and Uber Technologies stocks and cautiously optimistic on Super Micro Computer. Analysts currently see higher upside potential in MSTR than in the other two large-cap stocks. Wall Street is upbeat on Strategy stock, as it is an attractive Bitcoin proxy. Investors should be aware of the fact that, given its crypto exposure, MSTR stock is a high-risk, high-reward play.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
ConceptVines and Neovera Partner to Accelerate Secure AI Adoption for Organizations in Highly Regulated Industries
Joint offering delivers enterprise-grade cybersecurity with an AI-first foundation NEW YORK, June 12, 2025--(BUSINESS WIRE)--As Artificial Intelligence (AI) adoption accelerates across industries, enterprises are under mounting pressure to innovate faster, without exposing themselves to new forms of cyber and regulatory risk. For highly regulated sectors like banking and healthcare, the stakes are especially high: fragmented infrastructure, evolving compliance demands, and vulnerable data pipelines can derail even the most promising digital initiatives. To address these challenges, ConceptVines, an AI-first innovation and transformation platform, has partnered with Neovera, the trusted advisor providing full cybersecurity and cloud services to enterprises. Together, the companies are bridging innovation and cyber risk management, delivering secure, compliant, and scalable AI deployments for clients across banking, healthcare, and complex enterprise environments. "At ConceptVines, we believe security must be foundational, not an afterthought," said Jim Francis, CEO of ConceptVines. "This partnership brings together our AI-led innovations, including our SpeedX platform, with Neovera's deep cybersecurity expertise to ensure that every layer of our clients' AI infrastructure is secure by design. Together, we're setting a new standard for enterprise-grade AI deployments." At the heart of the partnership is a four-stage cybersecurity flywheel that mirrors a clinical model: starting with vulnerability assessments, moving into advisory and design, followed by integration of next-gen security solutions such as Palo Alto Networks, SentinelOne, CrowdStrike and others, and ultimately evolving into managed SecOps for long-term resilience. From automated threat detection to digital identity, data privacy, and AI governance frameworks, the partnership offers clients access to a unified approach for securing tomorrow's digital infrastructure. "As AI transforms every corner of business, the risks are too great to leave to generalists," said Scott Weinberg, CEO and founder of Neovera. "This partnership combines deep domain expertise in both cybersecurity and AI risk management, giving our clients the specialist support they need to move fast without compromising safety, trust, or compliance. The margin for error is zero, and together, we're helping organizations get it right the first time." ConceptVines is a trusted partner for industry-leading enterprises, delivering advanced Generative AI platforms and shaping the business models of the future. Businesses globally rely on Neovera for its advanced cloud and cybersecurity services, including identity and access management, vulnerability assessment and management, penetration testing, and more. Together, the two organizations are bringing end-to-end security into every layer of AI deployments. To learn more about the partnership, visit About ConceptVines ConceptVines is an AI-first innovation partner specializing in the design and deployment of secure, production-grade AI systems for complex enterprise environments. Through its SpeedX platform, ConceptVines enables organizations to operationalize generative AI, enterprise knowledge graphs, agent-based automation, and intelligent data orchestration across critical workflows. Combining strategic insight with deep technical execution, ConceptVines helps global enterprises move beyond pilots to fully embedded AI systems that drive measurable operational outcomes. With an AI-first foundation, ConceptVines provides the platforms, architectures, and applied AI expertise enterprises need to scale innovation securely and responsibly. To learn more about ConceptVines, visit or follow us on LinkedIn. About Neovera Neovera is the trusted advisor that provides full cybersecurity and cloud services to enterprises with complex challenges and demanding regulatory requirements. Businesses globally rely on Neovera to expertly design, build, secure, and manage their mission-critical business infrastructure backed by its deep expertise in cybersecurity and cloud domains. To learn more about Neovera, visit or follow us on LinkedIn. View source version on Contacts Media Contact Jason VancuraMarketbridge PR for NeoveraNeovera@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
24 minutes ago
- Yahoo
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ORR in Ph 1 patients with R/R NUP98r AML – NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced new data from the pivotal AUGMENT-101 trial of Revuforj® (revumenib), the Company's first-in-class menin inhibitor, in patients with relapsed or refractory (R/R) mutant NPM1 (mNPM1) and NUP98-rearranged (NUP98r) acute myeloid leukemia (AML). The data are being presented in posters at the 30th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy and virtually. 'The new data from AUGMENT-101 continue to highlight Revuforj's best-in-class profile and its potential to transform the treatment paradigm for acute leukemia patients with certain genetic alterations,' said Nick Botwood, M.B.B.S., Head of Research & Development and Chief Medical Officer at Syndax. 'The compelling AUGMENT-101 results led to the FDA approval of Revuforj for R/R acute leukemia with a KMT2A translocation and serve as the foundation for the supplemental NDA we submitted to the FDA for R/R mNPM1 AML, another area of high unmet need.' 'Revumenib has shown a potential best-in-class efficacy profile and the latest data in R/R mNPM1 AML underscore the opportunity for revumenib to become a standard of care treatment for this patient population in addition to R/R KMT2Ar acute leukemia,' said Ibrahim Aldoss, M.D., Associate Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation at the City of Hope. 'The revumenib data in R/R mNPM1 AML presented at EHA are impressive, with 26% of patients achieving CR/CRh and nearly 50% achieving an overall response with a medicine that was generally well-tolerated. Furthermore, the 23-month median overall survival observed in responders in a subgroup analysis is very encouraging.' Additional Results from R/R mNPM1 AML Patients in the Pivotal Phase 2 Portion of the AUGMENT-101 Trial of Revumenib The Phase 2 portion of the AUGMENT-101 trial of revumenib enrolled 84 patients with R/R mNPM1 AML. As previously reported, the primary endpoint was met in the protocol-defined primary analysis population which included the first 64 adults who met the efficacy evaluable criteria. At EHA 2025, the Company will highlight consistent results from all the efficacy-evaluable R/R mNPM1 AML patients (n=77) in the Phase 2 portion of AUGMENT-101 (DCO: September 2024). In this population, the median age was 63 (11-84), 20% had received four or more prior lines of therapy (median prior lines: 2), and 74% had previously received venetoclax. The complete remission plus complete remission with partial hematologic recovery (CR+CRh) rate was 26% (20/77; 95% CI: 17%-37%). The median duration of CR/CRh response was 4.7 months (95% CI: 2.1-8.2) and the median time to first CR/CRh was 2.8 months (range: 0.9-8.8). Minimal residual disease (MRD) status was assessed in 19 of 20 patients who achieved CR/CRh, 63% (12/19) of whom were MRD negative. The overall response rate (ORR)1 was 48% (37/77; 95% CI: 37%-60%). Of the patients who achieved an overall response, five patients proceeded to hematopoietic stem cell transplant (HSCT) while in remission, with three patients resuming revumenib after HSCT. Four patients were in CR or CRh and one was in morphologic leukemia-free state (MLFS) when they proceeded to HSCT. Newly shared data from this single-arm trial show that the median overall survival (OS) observed was 4.8 months (95% CI: 3.4-8.4) among all efficacy-evaluable Phase 2 R/R mNPM1 AML patients, based on the Kaplan-Meier estimate. A new subpopulation analysis that will be reported at a future medical meeting show that a median OS of 23.3 months (95% CI: 8.4-NR) was observed among the 37 patients who achieved an overall response, based on the Kaplan-Meier estimate. Additionally, newly shared analyses from all efficacy-evaluable Phase 2 R/R mNPM1 AML patients show that CR+CRh responses were observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax exposure. The CR+CRh rate was 25%, 20%, and 33% among patients with one, two, or three or more prior lines of therapy, respectively. The CR+CRh rate was 45% (95% CI: 23%-69%) among patients without prior venetoclax exposure and 19% (95% CI: 10%-32%) among patients with prior venetoclax exposure. The AUGMENT-101 Phase 2 safety population included 84 adult and pediatric patients with R/R mNPM1 AML. Detailed results from this safety population were previously published in the journal Blood and will be summarized in the EHA presentation. The safety profile observed with revumenib in this population was consistent with previously reported data. Revumenib was generally well-tolerated with 4.8% (4/84) of patients discontinuing treatment due to treatment-related adverse events. Results in R/R NUP98r AML in the Phase 1 Portion of AUGMENT-101 Trial of Revumenib The Phase 1 portion of the AUGMENT-101 trial of revumenib enrolled R/R acute leukemia patients with KMT2Ar, mNPM1, and other genetic alterations associated with upregulation of HOX, including five patients with NUP98-rearranged (NUP98r) AML. NUP98r is among a growing list of genetic abnormalities associated with upregulation of HOX in leukemia that are susceptible to menin inhibition in preclinical studies. Among the patients with R/R NUP98r AML, 60% (3/5) attained morphological remission, including one patient who proceeded to transplant, resumed revumenib post-transplant and was in maintenance cycle 10 as of the February 2024 data cutoff date. The safety profile of revumenib in patients with R/R NUP98r AML was consistent with previous reports observed in KMT2Ar or mNPM1 AML. To further explore the potential for menin inhibition in other genetic populations, a Phase 2 investigator-sponsored study evaluating revumenib in R/R acute leukemia associated with HOX upregulation, including patients with NUP98r AML, has been initiated (NCT06229912). Patients with NUP98r are also included in several other ongoing clinical trials of revumenib, such as the Phase 1 trial of revumenib in combination with intensive chemotherapy in newly diagnosed AML patients and the Phase 1/2 SAVE trial of revumenib in combination with venetoclax and decitabine/cedazuridine in R/R and newly diagnosed patients with AML or mixed-lineage acute leukemia (MPAL). In the SAVE trial, a 100% (5/5) ORR was observed in patients with R/R NUP98r AML (DCO: November 2024). Additional Revumenib Presentations at EHA 2025 In addition to newly shared data from patients with R/R mNPM1 AML and NUP98r in the AUGMENT-101 trial, an encore presentation of data from patients with R/R KMT2Ar acute leukemia in the pivotal Phase 2 portion of the trial will also be presented. The data will be featured in a poster session titled 'Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia.' Results from the pivotal AUGMENT-101 trial led to the FDA approval in November 2024 of Revuforj® (revumenib) for the treatment of R/R acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. Two other abstracts were accepted for publication-only. One is a 'trial in progress' abstract which describes the design of the ongoing Phase 1 study of revumenib in combination with intensive chemotherapy in newly diagnosed AML patients with KMT2Ar, mNPM1, or NUP98r. The second abstract describes real-world treatment patterns in patients with R/R mNPM1 AML in the U.S. between January 2009 and June 2024. The posters and publication-only abstracts have been published on the virtual EHA congress platform. Copies of the posters will be made available in the 'Publications & Meetings Presentations' section of the Syndax website. About Revuforj® (revumenib) Revuforj (revumenib) is an oral, first-in-class, selective menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. Revumenib is in development for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1). Positive pivotal data from the AUGMENT-101 trial in this population with revumenib as a monotherapy were recently published and the Company submitted a supplemental NDA for revumenib in R/R mNPM1 AML in April 2025. Additionally, multiple trials of revumenib in combination with standard-of-care agents in mNPM1 AML or KMT2A-rearranged acute leukemia are ongoing or planned across the treatment landscape, including in newly diagnosed patients. Revumenib was previously granted Orphan Drug Designation for the treatment of AML, ALL and acute leukemias of ambiguous lineage (ALAL) by the U.S. FDA and for the treatment of AML by the European Commission. The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and Breakthrough Therapy Designation for the treatment of adult and pediatric patients with R/R acute leukemia harboring a KMT2A rearrangement. IMPORTANT SAFETY INFORMATION WARNING: DIFFERENTIATION SYNDROME Differentiation syndrome, which can be fatal, has occurred with Revuforj. Signs and symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and renal dysfunction. If differentiation syndrome is suspected, immediately initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution. WARNINGS AND PRECAUTIONS Differentiation syndrome: Revuforj can cause fatal or life-threatening differentiation syndrome (DS). Symptoms of DS, including those seen in patients treated with Revuforj, include fever, dyspnea, hypoxia, peripheral edema, pleuropericardial effusion, acute renal failure, and/or hypotension. In clinical trials, DS occurred in 39 (29%) of 135 patients treated with Revuforj. DS was Grade 3 or 4 in 13% of patients and fatal in one. The median time to onset was 10 days (range 3-41 days). Some patients experienced more than 1 DS event. Treatment interruption was required for 7% of patients, and treatment was withdrawn for 1%. Reduce the white blood cell count to less than 25 Gi/L prior to starting Revuforj. If DS is suspected, immediately initiate treatment with systemic corticosteroids (e.g., dexamethasone 10-mg IV every 12 hours in adults or dexamethasone 0.25-mg/kg/dose IV every 12 hours in pediatric patients weighing less than 40 kg) for a minimum of 3 days and until resolution of signs and symptoms. Institute supportive measures and hemodynamic monitoring until improvement. Interrupt Revuforj if severe signs and/or symptoms persist for more than 48 hours after initiation of systemic corticosteroids, or earlier if life-threatening symptoms occur such as pulmonary symptoms requiring ventilator support. Restart steroids promptly if DS recurs after tapering corticosteroids. QTc interval prolongation: In the clinical trials, QTc interval prolongation was reported as an adverse reaction in 39 (29%) of 135 patients treated with Revuforj. QTc interval prolongation was Grade 3 in 12% of patients. The heart-rate corrected QT interval (using Fridericia's method) (QTcF) was greater than 500 msec in 8%, and the increase from baseline QTcF was greater than 60 msec in 18%. Revuforj dose reduction was required for 5% of patients due to QTc interval prolongation. QTc prolongation occurred in 16% of the 31 patients less than 17 years old, 33% of the 88 patients 17 years to less than 65 years old, and in 50% of the 16 patients 65 years or older. Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to treatment with Revuforj. Perform an electrocardiogram (ECG) prior to initiation of Revuforj, and do not initiate Revuforj in patients with QTcF >450 msec. Perform an ECG at least once weekly for the first 4 weeks and at least monthly thereafter. In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring may be necessary. Concomitant use with drugs known to prolong the QTc interval may increase the risk of QTc interval prolongation. Interrupt Revuforj if QTcF increases >480 msec and <500 msec, and restart Revuforj at the same dose twice daily after the QTcF interval returns to ≤480 msec Interrupt Revuforj if QTcF increases >500 msec or by >60 msec from baseline, and restart Revuforj twice daily at the lower-dose level after the QTcF interval returns to ≤480 msec Permanently discontinue Revuforj in patients with ventricular arrhythmias and in those who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia. Embryo-fetal toxicity: Revuforj can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Revuforj and for 4 months after the last dose of Revuforj. ADVERSE REACTIONSFatal adverse reactions occurred in 4 (3%) patients who received Revuforj, including 2 with differentiation syndrome, 1 with hemorrhage, and 1 with sudden death. Serious adverse reactions were reported in 99 (73%) patients. The most frequent serious adverse reactions (≥5%) were infection (24%), febrile neutropenia (19%), bacterial infection (17%), differentiation syndrome (12%), hemorrhage (9%), and thrombosis (5%). The most common adverse reactions (≥20%) including laboratory abnormalities, were hemorrhage (53%), nausea (51%), phosphate increased (50%), musculoskeletal pain (42%), infection (41%), aspartate aminotransferase increased (37%), febrile neutropenia (35%), alanine aminotransferase increased (33%), parathyroid hormone intact increased (33%), bacterial infection (31%), diarrhea (30%), differentiation syndrome (29%), electrocardiogram QT prolonged (29%), phosphate decreased (25%), triglycerides increased (25%), potassium decreased (24%), decreased appetite (24%), constipation (23%), edema (23%), viral infection (23%), fatigue (22%), and alkaline phosphatase increased (21%). DRUG INTERACTIONSDrug interactions can occur when Revuforj is concomitantly used with: Strong CYP3A4 inhibitors: reduce Revuforj dose Strong or moderate CYP3A4 inducers: avoid concomitant use with Revuforj QTc-prolonging drugs: avoid concomitant use with Revuforj. If concomitant use is unavoidable, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold Revuforj if the QTc interval is >480 msec. Restart Revuforj after the QTc interval returns to ≤480 msec. SPECIFIC POPULATIONSLactation: advise lactating women not to breastfeed during treatment with Revuforj and for 1 week after the last dose. Pregnancy and testing: Revuforj can cause fetal harm when administered to a pregnant woman. Verify pregnancy status in females of reproductive potential within 7 days prior to initiating Revuforj. Pediatric: monitor bone growth and development in pediatric patients. Geriatric: compared to younger patients, the incidences of QTc prolongation and edema were higher in patients 65 years and older. Infertility: based on findings in animals, Revuforj may impair fertility. The effects on fertility were reversible. To report SUSPECTED ADVERSE REACTIONS, contact Syndax Pharmaceuticals at 1-888-539-3REV or FDA at 1-800-FDA-1088 or Please see Full Prescribing Information, including BOXED WARNING. About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on X and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax's product candidates, the acceptance of Syndax and its partners' products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj's or Niktimvo's commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax's collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. All other trademarks are the property of their respective owners. References 1. Overall response rate (ORR) includes CR, CRh, CRp, CRi, MLFS, and PR; Composite complete remission (CRc) includes CR, CRh, CRp, and = Complete remissionCRh = Complete remission with partial hematologic recoveryCRp = Complete remission with incomplete platelet recoveryCRi = Complete remission with incomplete count recoveryMLFS = Morphologic leukemia-free statePR = Partial response Syndax Contact Sharon KlahreSyndax Pharmaceuticals, Tel 781.684.9827 SNDX-GError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Grupo Bimbo Reports Progress in Its Environmental Sustainability Strategy
The world's leading baking company presented its 2024 Annual Report: 'Actions that Transform,' highlighting progress on its 2030 and 2050 commitments It has more than 4,200 electric delivery vehicles, the largest fleet in Mexico and Latin America 94% of Grupo Bimbo's packaging is now recyclable HORSHAM, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- In celebration of World Environment Day, Grupo Bimbo, the world's leading baking company, presented its 2024 Annual Report: 'Actions that Transform,' which outlines business progress and advances toward its 2030 and 2050 Sustainability Strategy goals. As part of its sustainability strategy, Grupo Bimbo has established a comprehensive plan to protect and preserve natural systems through its priority. This plan is structured around three key pillars: Net Zero Carbon Emissions, Zero Waste, and Regenerative Agriculture. Through its Net Zero Carbon Emissions pillar, the company is implementing a range of strategies to achieve its goal of becoming a net zero carbon emissions company by 2050. One of these initiatives is sustainable mobility. Today, Grupo Bimbo operates more than 7,757 vehicles powered by alternative fuels. Of these, over 4,200 are electric, solidifying its leadership as the company with the largest electric delivery fleet in Latin America and Mexico. Under its Zero Waste pillar, Grupo Bimbo reported that 94% of its packaging is now recyclable and reaffirmed its goal that by 2025, 100% of its packaging will be recyclable, biodegradable, or compostable. Additionally, in terms of waste management, we have 80 bakeries and production facilities that send zero waste to landfill. Aligned with its Regenerative Agriculture pillar, the company has implemented these practices across nearly 300,000 hectares, with the goal of sourcing all key ingredients from land cultivated using regenerative methods by 2050. Alejandra Vázquez, VP Global Sustainability at Grupo Bimbo, stated: '2024 was a year of great progress and significant efforts to continue generating a positive impact on the planet, in the lives of our associates, and in the communities where we live and work. We are very proud of these achievements within our Sustainability Strategy, as we continue to take firm steps toward our purpose of Nourishing a Better World.' Recently, the bakery also shared progress on its other two priorities in its latest sustainability report. Under the priority, that is focused on offering better nutritional profiles, plant-based diets, and purpose-driven sustainable brands, Grupo Bimbo reported that 99% of its daily consumption products are free from artificial colors and flavors. Under the priority, aimed at strengthening communities and caring for our people, Grupo Bimbo highlighted the implementation of 267 community projects in 28 countries through its 'Good Neighbor' program, benefiting more than 530,000 people. To learn more about the company's progress in sustainability, visit Annual Report 2024. Contact: bbu@
